BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20150612T084517Z
DTSTART:20150703T140000Z
DTEND:20150703T150000Z
SUMMARY:Mitosis\, genome stability and cancer chemotherapy
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}u8a-iatdcka
 g-fh8m5q
DESCRIPTION:The next seminar in the ‘Celebrating Research Success in FLS’
  series will be given by Prof Stephen Taylor\, who is a member of the Ce
 ll and Cancer Biology Research Theme. \n\nAntimitotic drugs\, including 
 the microtubule stabilizer taxol\, are front-line chemotherapy agents us
 ed to treat breast\, ovarian and prostate cancer. However these drugs a 
 far from perfect\; we can’t predict which tumours will respond\, we don’
 t know how resistance develops\, plus toxicity can be a problem. To addr
 ess these limitations\, a new generation of inhibitors that disrupt mito
 sis without affecting microtubule dynamics are being developed\, yieldin
 g excellent drugs targeting mitotic kinesins and mitotic kinases. Howeve
 r these drugs have thus far not been impressive in the clinic\, further 
 highlighting our limited understanding of the mechanisms that dictate ce
 ll fate in response to mitotic disruption. Following a genome-wide siRNA
  screen we discovered that the oncogenic transcription factor MYC is a t
 axol sensitizer. Using time-lapse imaging to correlate mitotic behaviour
  with cell fate\, we show that MYC sensitizes cells to mitotic blockers 
 and agents that accelerate mitotic progression. Using gene expression pr
 ofiling and functional experiments we delineated a MYC-dependent apoptot
 ic sub-network required for death in mitosis and post-mitotic apoptosis.
  Experiments in mice show that MYC sensitizes intestinal epithelial cell
 s taxol-induced apoptosis\, and gene expression analysis of breast cance
 rs suggests that the mechanism influences tumour responses to chemothera
 py. Moving forward\, we hope that these results will open up opportuniti
 es for biomarkers and combination therapies that could enhance both trad
 itional and second-generation antimitotic agents.
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Michael Smith Lecture Theatre\, Michael Smith Building\, Manches
 ter
END:VEVENT
END:VCALENDAR